Besides the demonstration of the capability of LNP-miRs in combination with MAPKi to delay or impair the emergence of de novo drug resistance, another challenging field of study is the overcoming of acquired resistance to BRAF and MEK inhibitors in melanoma. This evidence concerns the gene BRAF and melanoma.